Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease
Wilson E, Young C, Benitez J, Vandijck M, Swarovski M, Shahid M, Corso N, Kennedy G, Trelle A, Channappa D, Belnap M, Lind B, Le Bastard N, Quinn J, Nairn A, Kerchner G, Sha S, Wagner A, Henderson V, Longo F, Wyss‐Coray T, Poston K, Mormino E, Andreasson K. Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.060879.Peer-Reviewed Original ResearchAlzheimer's Disease Research CenterPtau-181Disease Research CenterAlzheimer's diseaseCohort 1Positron emission tomographyCohort 2Prognostic performanceAntibody combinationsAD participantsAβ42/Aβ40 ratioPreclinical Alzheimer's diseaseClinical AD diagnosisPlasma p-tau181Longitudinal cognitive declineTau pathologyAD pathologyCSF biomarkersTau-PETP-tau181Outcome measuresPhosphorylated tauPET biomarkersAβ40 ratioCognitive decline